Figure 3.
Effect of delayed oseltamivir treatment in mice infected with lethal dose of A/Anhui/1/2013 (H7N9) influenza virus. BALB/c mice were infected intranasally with 3 MLD50 (102.5 plaque-forming units per mouse) of A/Anhui/1/2013 (H7N9) influenza virus and treated with oseltamivir starting 24, 48, or 72 hours postinfection (p.i.). Oseltamivir was administered by oral gavage twice a day for 5 days at dose of 5, 20, or 80 mg/kg/day. Placebo groups were gavaged twice a day with sterile water on the same schedule. Weight loss (A, C, and E) and survival (B, D, and F) of mice (10 mice per group) treated with oseltamivir at 5 mg/kg (A–D), 20 mg/kg (A–F), or 80 mg/kg (A–F) starting 24 hours (A and B), 48 hours (C and D), or 72 hours (E and F) p.i.